TCGA-A7-A2KD-01A-31R-A21T-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 23
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.440
- G2M_CHECKPOINT+0.380
- E2F_TARGETS+0.340
- INTERFERON_GAMMA_RESPONSE+0.330
- HEDGEHOG_SIGNALING+0.230
- NOTCH_SIGNALING+0.200
- ALLOGRAFT_REJECTION+0.180
- INFLAMMATORY_RESPONSE+0.180
- MITOTIC_SPINDLE+0.150
- APICAL_SURFACE+0.140
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.490
- OXIDATIVE_PHOSPHORYLATION-0.460
- HYPOXIA-0.320
- MYOGENESIS-0.320
- ADIPOGENESIS-0.290
- GLYCOLYSIS-0.270
- FATTY_ACID_METABOLISM-0.260
- PEROXISOME-0.260
- P53_PATHWAY-0.240
- UV_RESPONSE_UP-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AE6Y-TTP1-A-1-0-R-A741-41 | — | D | 0.760 |
| 2 | SRR650133 | — | — | 0.739 |
| 3 | TCGA-D8-A1Y0-01A-11R-A14M-07 | — | A | 0.738 |
| 4 | BS_6MZ7FRZH | EPN | Supratentorial EPN | 0.719 |
| 5 | TCGA-A2-A25C-01A-11R-A169-07 | — | B | 0.719 |
| 6 | 57f2cc66-9163-4e07-93f8-d5a2158e7125 | — | — | 0.715 |
| 7 | MDT-AP-1349 | Med | Medulloblastoma | 0.713 |
| 8 | SRR6079981 | — | — | 0.711 |
| 9 | TCGA-96-A4JL-01A-11R-A24Z-07 | — | cohortSQ1 | 0.704 |
| 10 | BS_H1ZS5FMZ | high-grade glioma | — | 0.702 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.050 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |